A Fresh Look at GT103 in Lung Cancer Treatment

GT103 is a unique human antibody designed to fight cancer by targeting the complement factor H. Scientists conducted a study to test its safety and effectiveness in patients with tough-to-treat lung cancer. The trial involved gradually increasing the drug's dose to find the highest amount that patients could safely handle. Thirty-one patients participated across three hospitals. Two serious side effects were reported at lower doses: kidney injury at 0. 3 mg/kg and colitis at 1 mg/kg.

No major issues were found at higher doses, and the maximum safe dose wasn't reached. None of the patients saw their tumors shrink, but nine patients (29%) had stable disease, and their average survival time was about six months. The drug's half-life was estimated to be around 6. 5 days. The recommended dose for further studies is 10 mg/kg every three weeks, but more tweaking is needed. The study confirmed that GT103 is safe and tolerable in refractory non-small cell lung cancer.

Actions